ArticleClinical medicine insights. Arthritis and musculoskeletal disorders2026
Systemic Immune-Inflammation Index as a Marker of Activity in Behcet's Uveitis.
Article in Clinical medicine insights. Arthritis and musculoskeletal disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review and meta-analysis of the systemic immune-inflammation index (SII) in rheumatic diseases.Frontiers in immunology · 2026Pooled it
- Complete blood count-derived inflammatory parameters in pediatric idiopathic uveitis.BMC ophthalmology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Behcet's disease (BD) is an immune-mediated disease with ocular involvement in ~70% cases. Clinical assessment of uveitis activity can be challenging in special situations. The Systemic Immune-Inflammation Index (SII), a novel biomarker, may aid assessment but remains unstudied in BD uveitis. Objective: To evaluate the levels of SII and other potential inflammatory biomarkers derived from full blood count (FBC) in patients with active uveitis in BD. Methods: This is a case-control study that included 3 groups; an active uveitis group with a confirmed diagnosis of BD, an inactive disease group with BD without any activity for at least 3 months, and a control group of age and sex-matched healthy adults. Full blood count was done for all participants from a venous sample. Neutrophil-lymphocyte ratio (NLR), Platelet-lymphocyte ratio (PLR), and SII (neutrophils × platelets/lymphocytes) were calculated and compared between the groups. Results: 58 subjects were enrolled; 24 patients with BD and current active uveitis, 15 patients with inactive BD, and 19 healthy matched volunteers. The NLR and PLR were significantly higher in the active uveitis group than in the inactive group. SII was higher in the active uveitis group compared with the inactive group ( Conclusion: SII was highest in BD patients with active uveitis, significantly differing from those with inactive disease and healthy controls, supporting its potential as a biomarker for uveitis activity. Further research is needed to explore its correlation with disease severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.